Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 4/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.35 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.34 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1634816 | 1.00 | DDB1 (0.42) | DDB1CRBNP2RX3UCHL1NR1H2 | |
| SCHEMBL3645554 | 1.00 | DDB1 (0.42) | DDB1CRBNP2RX3UCHL1NR1H2 | |
| SCHEMBL7945530 | 1.00 | DDB1 (0.42) | DDB1CRBNP2RX3UCHL1NR1H2 | |
| SCHEMBL8261917 | 0.91 | DDB1 (0.43) | DDB1CRBNP2RX3UCHL1NR1H2 | |
| SCHEMBL1635987 | 0.91 | DDB1 (0.43) | DDB1CRBNUCHL1NAMPTSTS | |
| SCHEMBL3691730 | 0.91 | DDB1 (0.43) | DDB1CRBNUCHL1NAMPTSTS | |
| SCHEMBL3691732 | 0.91 | DDB1 (0.43) | DDB1CRBNUCHL1NAMPTSTS | |
| SCHEMBL14963381 | 0.90 | DDB1 (0.42) | DDB1CRBNP2RX3UCHL1NR1H2 | |
| SCHEMBL6913773 | 0.90 | DDB1 (0.42) | DDB1CRBNP2RX3UCHL1NR1H2 | |
| SCHEMBL4655478 | 0.90 | DDB1 (0.42) | DDB1CRBNP2RX3UCHL1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932277-B2 | Peptide inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2185524-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | Intermune, Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20090297476-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2008141227-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090297476-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | VIP, HDGF, EIF2AK2 | DDB1 721/4885CRBN 1922/4885P2RX3 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.